Latest News about GSK
Recent news which mentions GSK
Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial
March 15, 2022
From Benzinga
GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows
March 11, 2022
From Benzinga
7 Drug Stocks To Consider After the Viatris Plunge
March 10, 2022
From InvestorPlace
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
March 07, 2022
From Benzinga
1 Healthcare Stock That Could Fly Higher After a Strong Q4
March 05, 2022
From Motley Fool
From Motley Fool
From Benzinga
Need an Extra $1,000 Per Year? Buy and Hold These 2 Stocks
March 01, 2022
From Motley Fool
From Benzinga
3 Pharma Stocks That Retired Investors Should Love
February 26, 2022
From Motley Fool
Does CBD Have To Be Water Soluble? One Group Of Scientists Say Yes For Better Absorption
February 25, 2022
From Benzinga
From Benzinga
CDC expected to loosen COVID face-mask advice later Friday, and Canada authorizes first plant-based vaccine
February 25, 2022
Tickers
GSK
From MarketWatch
Canada Approves First Plant-Based COVID-19 Vaccine
February 25, 2022
From Benzinga
Why Moderna Stock Is Falling Today
February 23, 2022
From Motley Fool
From Benzinga
WHO says omicron subvariant is not stopping global cases from falling, and U.S. nearing 940,000 COVID deaths
February 23, 2022
From MarketWatch
From MarketWatch
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline
February 18, 2022
From Benzinga
Want To Collect $200 Every Month? Invest $49,334 in These 3 Stocks
February 18, 2022
From Motley Fool
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
February 18, 2022
From Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
From Benzinga
After Falling 67% in 1 Year, Is 23andMe Undervalued?
February 16, 2022
From Motley Fool
Inside Gilead's Lackluster $7.2 Billion Q4 Earnings
February 16, 2022
From Motley Fool
The Best Russell 2000 Stocks to Buy Before they Rebound
February 15, 2022
From InvestorPlace
4 Green Flags for 23andMe's Future
February 15, 2022
From Motley Fool
Tracking Gilead's 4 Big Stories and a Lawsuit in 2022
February 15, 2022
From Motley Fool
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.